CD19-Car T Cell Therapy for the Treatment of Older Adults With Acute Lymphoblastic Leukemia in First Remission

Summary

This phase I trial tests the safety, side effects, and best dose of autologous anti-CD19 CAR-expressing T lymphocytes (CD19-CAR T cells) in older adults with B-cell acute lymphoblastic leukemia. Chimeric antigen receptor (CAR) T-cell therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient's blood. Then the gene for a special receptor that binds to a certain protein on the patient's cancer cells is added to the T cells in the laboratory. The special receptor is called a chimeric antigen receptor (CAR). Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of B-cell acute lymphoblastic leukemia.

Timeline

Start

2023-04-26

Primary completion

2026-07-24

Completion

2026-07-24

Publications

• Aldoss I, Goldberg L, Zhang J, Artz AS, Clark MC, Guan M, Espinosa R, Abimannan T, Wu J, Garcia B, Haas ER, Pathak KV, Lovell B, Pirrotte P, Agrawal V, Sanani N, Kasten S, Tilakawardane D, Wagner JR, Paul J, Shan H, Khaled S, Budde LE, Koller PB, Stein AS, Pullarkat VA, Salhotra A, Aribi A, Marcucci G, Wang X, Forman SJ. CAR T Cell Therapy as a Definitive Consolidation for Older Adults with B-ALL in First Complete Remission. Blood Adv. 2026 Jun 24:bloodadvances.2026020963. doi: 10.1182/bloodadvances.2026020963. Online ahead of print.

Drugs

Indications